Compare Petróleo Brasileiro SA (PBR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Spyre Therapeutics Inc. Common Stock — how do they compare? Petróleo Brasileiro SA trades at $25.79 (market cap $159.16B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Petróleo Brasileiro SA is far larger — about 21.7× Spyre Therapeutics Inc. Common Stock's market cap, and Petróleo Brasileiro SA pays a 6.46% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 26 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PBR | SYRE | |
|---|---|---|
Market Cap | $159.16B | $7.35B |
Volume | 19,717,211 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $25.94 | $108.92 |
52-Week Low | $11.54 | $22.18 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $219.58B | $6.35B |
Dividend Yield | 6.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.50, up 0.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings that beat estimates, with net income nearly doubling year-over-year on record production. Recent news highlights a new oil discovery off Amapa and a 22-year LNG supply deal with Cheniere Energy, supporting long-term growth prospects.
PBR presents a compelling value with a low P/E of 6.44 and robust profitability, including a 30.77% ROE. However, the stock trades above the analyst consensus price target of $22.33, and net cash flow turned negative in 2026. Key risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
